GlassScriptPhysician profile
Megan Matocha
NPI 1700267572
$3,040.75
in general payments reported to CMS, 2019-2025
13 companies · $684 in 2025
The $684 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $12.64 · 2021: $518 · 2022: $347 · 2023: $805 · 2024: $429 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,346.30 | 2022-2025 | Infuse, Ultra Multifocal Toric, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $476.74 | 2019-2021 | |
| Alcon Vision LLC | $289.29 | 2019-2025 | Total30, Precision7, Precision 1 |
| Glaukos Corporation | $216.47 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Novartis Pharmaceuticals Corporation | $212.09 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $155.66 | 2021-2025 | Acuvue |
| Coopervision INC. | $113.83 | 2024 | Myday Contact Lens |
| Optos, INC. | $93.75 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $33.26 | 2024-2025 | Xdemvy |
| Allergan, INC. | $32.28 | 2020-2022 | |
| Abbvie INC. | $29.07 | 2023 | |
| Oyster Point Pharma, INC. | $21.06 | 2022 | |
| Synergeyes, INC. | $20.95 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Matocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.